Telbivudine
Telbivudine (pronounced as tel-BIV-ue-deen) is an antiviral drug used in the treatment of hepatitis B infection. It is marketed under the brand names Sebivo, Tyzeka, and Revovir.
Etymology
The name "Telbivudine" is derived from its chemical structure. It is a synthetic thymidine nucleoside analogue, where "telbi-" is a prefix used in chemical nomenclature to denote a synthetic derivative, and "-vudine" is a common suffix for nucleoside analogues.
Pharmacology
Telbivudine is a nucleoside analogue, which means it mimics the structure of one of the building blocks of DNA. It works by inhibiting the reverse transcriptase enzyme, which is necessary for the hepatitis B virus to replicate in the body. By blocking this enzyme, Telbivudine prevents the virus from multiplying, thereby reducing the amount of virus in the body.
Usage
Telbivudine is used for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
Side Effects
Common side effects of Telbivudine include fatigue, headache, dizziness, and gastrointestinal symptoms such as nausea, diarrhea, and abdominal pain. In rare cases, it can cause muscle pain or weakness, which may be a sign of a serious condition called myopathy.
Related Terms
See Also
External links
- Medical encyclopedia article on Telbivudine
- Wikipedia's article - Telbivudine
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski